@article{oai:kanazawa-u.repo.nii.ac.jp:00027040,
 author = {Yamada, Tadaaki and Ohtsubo, Koushiro and Izumi, Kouji and Takeuchi, Shinji and Mouri, Hisatsugu and Yamashita, Kaname and Yasumoto, Kazuo and Ghenev, Peter and Kitagawa, Satoshi and Yano, Seiji},
 issue = {6},
 journal = {International Journal of Clinical Oncology},
 month = {Dec},
 note = {We report the case of a 67-year-old man with metastatic papillary renal cell carcinoma (RCC) who developed bloody sputum after the administration of sunitinib. Chest computed tomography revealed diffuse ground-glass opacity lesions, and bloody bronchoalveolar lavage fluid was obtained by flexible bronchoscopy. The abnormal shadows promptly regressed after withdrawal of sunitinib. In four cycles of sunitinib treatment, he suffered from controllable diffuse alveolar hemorrhage. Finally, he died of respiratory failure 8 months after onset. This is the first case report of diffuse alveolar hemorrhage as an adverse effect of sunitinib in metastatic papillary RCC. Care should be taken with pulmonary hemorrhage in the use of anti-angiogenesis agents in not only squamous cell lung cancer, but also metastatic lung tumors. © 2010 Japan Society of Clinical Oncology., 金沢大学附属病院がん高度先進治療センター},
 pages = {638--641},
 title = {Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib},
 volume = {15},
 year = {2010}
}